iRhythm Technologies (IRTC)
(Delayed Data from NSDQ)
$75.04 USD
+2.60 (3.59%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $75.04 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$75.04 USD
+2.60 (3.59%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $75.04 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth F Momentum D VGM
Zacks News
Nextgen Healthcare (NXGN) Q3 Earnings Miss Estimates
by Zacks Equity Research
Nextgen Healthcare (NXGN) delivered earnings and revenue surprises of -3.70% and 1.08%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
IRhythm Technologies (IRTC) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
iRhythm Technologies (IRTC) delivered earnings and revenue surprises of 23.17% and 2.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
IRhythm Technologies (IRTC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
iRhythm Technologies (IRTC) delivered earnings and revenue surprises of 15.96% and 2.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate iRhythm Technologies (IRTC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
IRhythm Technologies (IRTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
iRhythm Technologies (IRTC) Moves 5.1% Higher: Will This Strength Last?
by Zacks Equity Research
iRhythm Technologies (IRTC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XHE
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
IRhythm Technologies (IRTC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
iRhythm Technologies (IRTC) delivered earnings and revenue surprises of 24.53% and 5.97%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
IRhythm Technologies (IRTC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
IRhythm Technologies (IRTC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XHE
iRhythm Technologies (IRTC) Soars 4.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
iRhythm Technologies (IRTC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
iRhythm Technologies (IRTC) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
iRhythm Technologies (IRTC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
IRhythm Technologies (IRTC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
iRhythm Technologies (IRTC) delivered earnings and revenue surprises of 9.84% and 4.61%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XHE
Strength Seen in iRhythm Technologies (IRTC): Can Its 27.6% Jump Turn into More Strength?
by Zacks Equity Research
iRhythm Technologies (IRTC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XHE
IRhythm Technologies (IRTC) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
iRhythm Technologies (IRTC) delivered earnings and revenue surprises of 25.69% and 2.27%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
IRhythm Technologies (IRTC) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
IRhythm Technologies (IRTC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IRHYTHM TECH (IRTC) Moves 35% Higher: Will This Strength Last?
by Zacks Equity Research
IRHYTHM TECH (IRTC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
IRHYTHM TECH (IRTC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
IRHYTHM TECH (IRTC) delivered earnings and revenue surprises of 39.18% and 11.42%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate IRHYTHM TECH (IRTC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
IRHYTHM TECH (IRTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for May 26th
by Zacks Equity Research
ALBO, EBMT, GAN, IRTC, and WLKP have been added to the Zacks Rank #5 (Strong Sell) List on May 26, 2021
New Strong Sell Stocks for May 14th
by Zacks Equity Research
AXDX, CDR, FPAY, GCI, and IRTC have been added to the Zacks Rank #5 (Strong Sell) List on May 14, 2021